ONCAlert | Upfront Therapy for mRCC
Hodgkins Lymphoma Case Studies

Case Studies: Optimal Management of Stage IIIA Hodgkin's Lymphoma

Leo Gordon, MD, elucidates the diagnosis, treatment, and outcome of a 52-year-old woman who presented with stage IIIA Hodgkin’s lymphoma.

Optimal Management of Stage IIIA Hodgkin's Lymphoma

A 52-Year-Old Woman With Stage IIIa Hodgkin's Lymphoma

  • History and physical exam
    • A 52-year-old female presented with abdominal pain
    • Labs: B12 deficiency, albumin 3.5 mg/dL, Hgb 11.5 g/dL, white cell and lymphocyte counts WNL
    • No B symptoms
  • Right cervical excisional biopsy: classical Hodgkin’s disease, nodular sclerosis, stage IIIa
  • Cardiac and lung function were normal
  • IPS 2
  • AVD + brentuximab (1.2 mg/kg) q2w x 6 cycles was initiated 2.5 months later

Treatment Course

Cycle 1, d 1

Leg cramping; hospitalized for neutropenic fever (d 7-14)

Cycle 1, d 15

Bone pain; constipation

Cycle 2, d 1

AVD + brentuximab delayed 1 wk due to neutropenia hospitalization; elongated QT interval (drug related); PPI initiated for reflux; constipation causing abdominal pain; numbness in hands

Cycle 2, d 5

GERD, constipation, and neuropathy unchanged

Cycle 2, d 16

Hospitalized 8 days for neutropenic fever; discharged on amoxicillin (infection source unknown)

Interim PET-CT

Complete response (Deauville score 2)

Cycle 3, d 1

Filgrastim 5 mgc/kg qd, d 5-10; treatment well tolerated; ED for bronchitis (azithromycin), good response

Cycle 3, d 15

Treatment well tolerated; ANC > 3 throughout treatment; grade 1 neuropathy (numbness in fingertips, palms, and toes)

Cycle 4, d 1

Treatment tolerated well; no fever; grade 1 neuropathy

Cycle 4, d 15

Brentuximab dose reduced to 0.8 mg/kg, due to grade 2 peripheral sensory neuropathy; transient grade 1 skin and mucosal abnormalities around day 8

Cycle 5, d 1

Grade 2 neuropathy; pregabalin for muscle pain and weakness initiated

Cycle 5, d 15

EF < 50%; slightly worsened neuropathy (impacting work and daily life); doxorubicin held (in consult with cardiologist)

Cycle 6, d 1

Doxorubicin restarted (per cardiologist/> 50% EF); grade 3 neuropathy; leg weakness increased; brentuximab held

Cycle 6, d 15

Neuropathy continues; brentuximab held

PET/final restaging

Negative

 

  • Neuropathy resolved; no limitations by 6 months post-treatment
Publications
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.